Pregabalin-associated movement disorders: A literature review.
CI-1008
drug induced
literature review
movement disorder
pregabalin
Journal
Brain circulation
ISSN: 2455-4626
Titre abrégé: Brain Circ
Pays: India
ID NLM: 101669876
Informations de publication
Date de publication:
Historique:
received:
28
11
2019
revised:
12
05
2020
accepted:
03
06
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
10
10
2020
Statut:
epublish
Résumé
Central nervous system adverse effects are commonly reported with pregabalin (PGB). On the other hand, movement disorders (MDs) associated with this drug were rarely described. However, their occurrence could significantly affect the quality of life of PGB users. This literature review aims to evaluate the clinical epidemiological profile, pathological mechanisms, and management of PGB-associated MDs. Relevant reports in six databases were identified and assessed by two reviewers without language restriction. A total of 46 reports containing 305 cases from 17 countries were assessed. The MDs encountered were as follows: 184 individuals with ataxia, 61 with tremors, 39 with myoclonus, 8 with parkinsonism, 1 with restless legs syndrome, 1 with dystonia, 1 with dyskinesia, and 1 with akathisia. The mean age was 62 years (range: 23-94). The male sex was slightly predominant with 54.34%. The mean PGB dose when the MD occurred was 238 mg, and neuropathic pain was the most common indication of PGB. The time from PGB start to MD was < 1 month at 75%. The time from PGB withdrawal to recovery was < 1 week at 77%. All the individuals where the follow-up was reported had a full recovery. The most common management was PGB withdrawal. In the literature, the majority of the cases did not report information about timeline events, neurological examination details, or electrodiagnostic studies. The best management for all MDs is probably PGB withdrawal. If the patient is on dialysis program, perhaps an increased number of sessions will decrease recovery time. Furthermore, the addition of a benzodiazepine could accelerate recovery.
Identifiants
pubmed: 33033779
doi: 10.4103/bc.bc_57_19
pii: BC-6-96
pmc: PMC7511912
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
96-106Informations de copyright
Copyright: © 2020 Brain Circulation.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Brain Res. 1990 Feb 26;510(1):104-7
pubmed: 1691042
J Clin Neurosci. 2019 Mar;61:225-234
pubmed: 30381161
Epilepsia. 2004 Jan;45(1):20-7
pubmed: 14692903
Clin Neuropharmacol. 2009 Nov-Dec;32(6):353-4
pubmed: 19952879
J Neurol Sci. 2017 Nov 15;382:36-39
pubmed: 29111014
Ann Acad Med Singap. 2020 Apr;49(4):236-251
pubmed: 32419008
Pain Physician. 2012 May-Jun;15(3):E349-351
pubmed: 22622921
Brain Sci. 2017 Aug 14;7(8):
pubmed: 28805718
Parkinsonism Relat Disord. 2015 Jul;21(7):823-4
pubmed: 25956204
Mov Disord. 1998 May;13(3):453-6
pubmed: 9613736
Neurosci Res. 2008 Feb;60(2):162-9
pubmed: 18054402
Brain. 1978 Sep;101(3):447-60
pubmed: 101279
J Hosp Med. 2011 Feb;6(2):103-4
pubmed: 21290583
Nat Rev Drug Discov. 2005 Jun;4(6):455-6
pubmed: 15959952
Am J Kidney Dis. 2009 Dec;54(6):1127-30
pubmed: 19493601
Psychiatry Investig. 2009 Dec;6(4):313-5
pubmed: 20140131
Epilepsia. 2011 Apr;52(4):826-36
pubmed: 21320112
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Nat Rev Neurosci. 2012 Jul 18;13(8):542-55
pubmed: 22805911
BMJ Case Rep. 2012 Nov 28;2012:
pubmed: 23192584
Therapie. 2017 Jun;72(3):395-396
pubmed: 27817842
J Clin Psychopharmacol. 2016 Dec;36(6):740-742
pubmed: 27755156
Lancet Neurol. 2004 Oct;3(10):598-607
pubmed: 15380156
Clin Neuropharmacol. 2020 May/Jun;43(3):66-80
pubmed: 32384309
Ann Pharmacother. 2013 Apr;47(4):592-3
pubmed: 23535811
Epilepsia. 2005 Dec;46(12):1926-36
pubmed: 16393158
Psychiatry Investig. 2009 Jun;6(2):55-8
pubmed: 20046375
J Neurophysiol. 2003 Sep;90(3):1363-74
pubmed: 12966170
Neurology. 2003 May 27;60(10):1631-7
pubmed: 12771254
Cochrane Database Syst Rev. 2014 Mar 12;(3):CD005612
pubmed: 24623260
Mov Disord. 2020 Jan;35(1):176-180
pubmed: 31633228
Neurology. 2005 Feb 8;64(3):475-80
pubmed: 15699378
Anticancer Res. 2010 Jul;30(7):2927-33
pubmed: 20683034
Ann Pharmacother. 2005 Dec;39(12):2029-37
pubmed: 16288079
Adv Neurol. 1986;43:137-56
pubmed: 3946109
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD007076
pubmed: 19588419
NDT Plus. 2011 Apr;4(2):138
pubmed: 25984138
Brain. 2002 Apr;125(Pt 4):861-70
pubmed: 11912118
Epilepsy Res. 2010 Sep;91(1):10-9
pubmed: 20696552
Epilepsy Behav. 2008 Aug;13(2):397-401
pubmed: 18554985
Mov Disord. 2009 Oct 15;24(13):2028-9
pubmed: 19642217
Epilepsy Behav. 2008 Oct;13(3):554-6
pubmed: 18579443
Expert Rev Neurother. 2019 Apr;19(4):325-331
pubmed: 30874443
Yeungnam Univ J Med. 2018 Dec 31;35(2):240-243
pubmed: 31620602
J Pain Symptom Manage. 2019 Jan;57(1):1-9
pubmed: 30359684
Epilepsy Behav Case Rep. 2012 Nov 07;1:10-3
pubmed: 25688046
Prog Neurobiol. 1996 Nov;50(4):381-425
pubmed: 9004351
Am J Phys Med Rehabil. 2005 Sep;84(9):724
pubmed: 16141753
Epilepsia. 2009 Mar;50(3):464-74
pubmed: 19222545
Neuropsychiatr Dis Treat. 2008 Dec;4(6):1193-201
pubmed: 19337459
Br J Gen Pract. 1995 May;45(394):261-8
pubmed: 7619574
Epilepsia. 2001 Jun;42(6):790-2
pubmed: 11422338
J Clin Psychiatry. 2011 Mar;72(3):273-85
pubmed: 20673558
Trends Pharmacol Sci. 2013 Jun;34(6):332-9
pubmed: 23642658
Indian J Nephrol. 2014 Jan;24(1):48-50
pubmed: 24574633
Epilepsy Behav. 2007 Nov;11(3):471-3
pubmed: 17900992
Front Hum Neurosci. 2019 Oct 04;13:336
pubmed: 31636553
Prague Med Rep. 2020;121(1):5-24
pubmed: 32191616
Eur J Neurosci. 2007 Oct;26(7):1853-61
pubmed: 17868370
Epilepsy Behav. 2008 Aug;13(2):418-20
pubmed: 18492617
Neurol India. 2020 Nov-Dec;68(6):1469-1471
pubmed: 33342895
Curr Treat Options Neurol. 2016 May;18(5):21
pubmed: 27039330
Acta Neurol Scand. 2007 May;115(5):347-50
pubmed: 17489946